Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: A perspective review

Therapeutic Advances in Hematology

Volumn 6, Issue 4, 2015, Pages 202-208

  Sawas, Ahmed ^a   O'connor, Owen A ^a   Radeski, Dejan ^b  

^a NewYork Presbyterian Hospital   (United States)

^b WESTERN DIAGNOSTIC PATHOLOGY   (Australia)

Author keywords

belinostat; histone deacetylase inhibitors; peripheral T cell lymphoma; PXD101

Indexed keywords

EID: 84993683912     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620715592567     Document Type: Review

References (28)

1. Akagi T. Takahashi N. Yamaguchi K. Ishizawa K. Murai K. Tajima K. et al. (2011) Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum. J Clin Exp Hematop 51 (1): 29–35.
2. Bolden J. Peart M. Johnstone R. (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5 (9): 769–784.
3. Bose P. Dai Y. Grant S. (2014) Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143 (3): 323–336.
4. Bosshart H. (2003) Interleukin-3 receptors in Hodgkin's disease. Am J Pathol 162 (1): 355–356; author reply 356–357.
5. Coiffier B. Pro B. Prince M. Foss F. Sokol L. Greenwood M. et al. (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30 (6): 631–636.
6. Ellin F. Landstrom J. Jerkeman M. Relander T. (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124 (10): 1570–1577.
7. Furumai R. Matsuyama R. Kobashi N. Lee K. Nishiyama M. Nakajima H. et al. (2002) FK 228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62 (17): 4916–4921.
8. Gimsing P. Hansen M. Knudsen L. Knoblauch P. Christensen I. Ooi C. et al. (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 81 (3): 170–176.
9. Glozak M. Sengupta N. Zhang X. Seto E. (2005) Acetylation and deacetylation of non-histone proteins. Gene 363: 15–23.
10. Hamadani M. Abu Kar S. Usmani S. Savani B. Ayala E. Kharfan-Dabaja M. (2014) Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. Semin Hematol 51 (1): 73–86.
11. Juergens R. Wrangle J. Vendetti F. Murphy S. Zhao M. Coleman B. et al. (2011) Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1 (7): 598–607.
12. Kalac M. Scotto L. Marchi E. Amengual J. Seshan V. Bhagat G. et al. (2011) HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 118 (20): 5506–5516.
13. Munster P. Thurn K. Thomas S. Raha P. Lacevic M. Miller A. et al. (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104 (12): 1828–1835.
14. O'Connor O. Bhagat G. Ganapathi K. Pedersen M. D'Amore F. Radeski D. et al. (2014) Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice. Clin Cancer Res 20 (20): 5240–5254.
15. O'Connor O. Heaney M. Schwartz L. Richardson S. Willim R. MacGregor-Cortelli B. et al. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24 (1): 166–173.
16. O'Connor O. Masszi T. Savage K. Pinter-Brown L. Foss F. Popplewell L. et al. (2013) Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. J Clin Oncol 31 (15): abstract 8507.
17. O'Connor O. Pro B. Pinter-Brown L. Bartlett N. Popplewell L. Coiffier B. et al. (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29 (9): 1182–1189.
18. Olsen E. Kim Y. Kuzel T. Pacheco T. Foss F. Parker S. et al. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109–3115.
19. Paoluzzi L. Scotto L. Marchi E. Zain J. Seshan V. O'Connor O. (2010) Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 16 (2): 554–565.
20. Piekarz R. Frye R. Prince H. Kirschbaum M. Zain J. Allen S. et al. (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117 (22): 5827–5834.
21. Poole R. (2014) Belinostat: first global approval. Drugs 74 (13): 1543–1554.
22. Pro B. Advani R. Brice P. Bartlett N. Rosenblatt J. Illidge T. et al. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30 (18): 2190–2196.
23. Puig N. Wang L. Seshadri T. al-Farsi K. Keating A. Crump M. Kuruvilla J. (2013) Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma. Leuk Lymphoma 54 (3): 507–513.
24. Rosato R. Grant S. (2005) Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 9 (4): 809–824.
25. Steele N. Plumb J. Vidal L. Tjornelund J. Knoblauch P. Rasmussen A. et al. (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14 (3): 804–810.
26. West A. Johnstone R. (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124 (1): 30–39.
27. Zain J. Foss F. Diefenbach C. Petrylak D. Narwal A. Neylon E. et al. (2011) Preliminary results of an ongoing phase I trial of oral belinostat a novel histone deacetylase inhibitor in patients with lymphoid malignancies. Blood (ASH Annual Meeting) 118 (21): Abstr 3710.
28. Zain J. O'Connor O. (2010) Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol 92 (1): 33–44.